| Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and ...

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

original posters to be presented on cell therapy, patient-reported outcomes, innovative recruitment strategies, and clinical ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug ...

Acknowledging China's innovative biotech environment, UK-headquartered pharmaceutical company AstraZeneca said it is ...

Pharmexcil seeks suggestions on regulatory gap in new drug approvals identified by the CDSCO: Shardul Nautiyal, Mumbai Saturday, October 25, 2025, 08:00 Hrs [IST] The Pharmaceutic ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology ...

The UK is facing a pharma exodus. Major pharmaceutical companies have withdrawn about £2 billion in proposed investment from ...

With market caps in the trillions, these tech behemoths are establishing a growing presence in drug development. Here’s what ...

Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...

Investors were treated to presentations from ASX companies across a range of industries amid the iconic backdrop of the ...

The perinatal period and early childhood represent critical windows of development, where interventions have lifelong ...